Department of Human Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
PPAR Res. 2008;2008:250568. doi: 10.1155/2008/250568.
Induction of differentiation and apoptosis in cancer cells by ligands of PPARgamma is a novel therapeutic approach to malignant tumors. Chondrosarcoma (malignant cartilage tumor) and OUMS-27 cells (cell line established from grade III human chondrosarcoma) express PPARgamma. PPARgamma ligands inhibited cell proliferation in a dose-dependent manner, and induced apoptosis of OUMS-27. The higher-grade chondrosarcoma expressed a higher amount of antiapoptotic Bcl-xL in vivo. The treatment of OUMS-27 by 15d-PGJ(2), the most potent endogenous ligand for PPARgamma, downregulated expression of Bcl-xL and induced transient upregulation of proapoptotic Bax, which could accelerate cytochrome c release from mitochondria to the cytosol, followed by induction of caspase-dependent apoptosis. 15d-PGJ(2) induced the expression of CDK inhibitor p21 protein in human chondrosarcoma cells, which appears to be involved in the mechanism of inhibition of cell proliferation. These findings suggest that targeted therapy with PPARgamma ligands could be a novel strategy against chondrosarcoma.
配体诱导 PPARγ 分化和凋亡是治疗恶性肿瘤的新方法。软骨肉瘤(恶性软骨肿瘤)和 OUMS-27 细胞(从 III 级人软骨肉瘤建立的细胞系)表达 PPARγ。PPARγ 配体呈剂量依赖性抑制细胞增殖,并诱导 OUMS-27 细胞凋亡。体内高等级软骨肉瘤表达更高水平的抗凋亡 Bcl-xL。15d-PGJ(2)(PPARγ 的最有效内源性配体)处理 OUMS-27 细胞,下调 Bcl-xL 的表达并诱导促凋亡 Bax 的短暂上调,这可能导致细胞色素 c 从线粒体释放到细胞质,随后诱导 caspase 依赖性凋亡。15d-PGJ(2)诱导人软骨肉瘤细胞中 CDK 抑制剂 p21 蛋白的表达,这似乎涉及细胞增殖抑制的机制。这些发现表明,PPARγ 配体的靶向治疗可能是治疗软骨肉瘤的一种新策略。